Alzheimer's Disease Market Research
What is Alzheimer’s Disease (AD)?
Alzheimer’s disease (AD) is the most common cause of dementia, a brain disorder that gets worse over time. It is characterized by changes in the brain, such as the accumulation of amyloid plaques, causing brain cells to die. Alzheimer’s disease causes a gradual decline in memory, thinking, behavior and social skills. Currently, treatments are focused on maintaining mental functions and managing the behavioral aspects of day-to-day life.
Spherix Global Insights – Neurology – Alzheimer’s Disease (AD)
Spherix’s studies publishing this year covering Alzheimer’s Disease include:
- Market Dynamix™: Alzheimer’s Disease (US)
- RealTime Dynamix™: Alzheimer’s Disease (EU5)
- Launch Dynamix™: Donanemab (Eli Lilly) in Alzheimer’s Disease (US)*
- Launch Dynamix™: Leqembi (Eisai/Biogen) in Alzheimer’s Disease (US)
- Patient Chart Dynamix™: Alzheimer’s Disease (US)
- Special Topix™: Alzheimer’s Disease: Symptomatics (US)
- Special Topix™: Disruptive Events in Alzheimer’s and ALS (US)
*Pending approvals and launch
Spherix’s Market Dynamix™ service is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
RealTime Dynamix™ is an independent service providing strategic guidance through quarterly or semiannual reports, which include market trending and a fresh infusion of event-driven and variable content with each wave. The reports provide an unbiased view of the competitive landscape within rapidly evolving specialty markets, fueled by robust HCP primary research and our in-house team of experts.
Spherix’s Launch Dynamix™ service consists of two parts: monthly KPI tracking and quarterly deep dives. Monthly KPIs provide benchmarking of newly launched products for the first eighteen months of commercial availability, and quarterly deep dive reports includes promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
Spherix’s Special Topix™ service is an independent service that includes access to a report or series of reports based on current events or topics of interest in specialty markets covered by Spherix.
Follow us for neurology industry news, insights & analysis:
https://www.linkedin.com/company/spherix-global-insights/
For Guests & Current Clients
For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here:
